![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMED2 |
Gene summary for TMED2 |
![]() |
Gene information | Species | Human | Gene symbol | TMED2 | Gene ID | 10959 |
Gene name | transmembrane p24 trafficking protein 2 | |
Gene Alias | P24A | |
Cytomap | 12q24.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q15363 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10959 | TMED2 | GSM4909281 | Human | Breast | IDC | 2.66e-43 | 6.86e-01 | 0.21 |
10959 | TMED2 | GSM4909286 | Human | Breast | IDC | 7.85e-03 | -7.73e-03 | 0.1081 |
10959 | TMED2 | GSM4909288 | Human | Breast | IDC | 3.87e-02 | -2.37e-01 | 0.0988 |
10959 | TMED2 | GSM4909290 | Human | Breast | IDC | 1.92e-05 | 3.24e-01 | 0.2096 |
10959 | TMED2 | GSM4909294 | Human | Breast | IDC | 1.30e-07 | -3.25e-01 | 0.2022 |
10959 | TMED2 | GSM4909296 | Human | Breast | IDC | 6.23e-13 | -1.29e-01 | 0.1524 |
10959 | TMED2 | GSM4909297 | Human | Breast | IDC | 4.31e-30 | 1.98e-01 | 0.1517 |
10959 | TMED2 | GSM4909301 | Human | Breast | IDC | 9.18e-05 | -1.96e-01 | 0.1577 |
10959 | TMED2 | GSM4909304 | Human | Breast | IDC | 1.09e-12 | 4.44e-01 | 0.1636 |
10959 | TMED2 | GSM4909305 | Human | Breast | IDC | 1.02e-06 | 3.15e-01 | 0.0436 |
10959 | TMED2 | GSM4909306 | Human | Breast | IDC | 1.29e-04 | 3.35e-01 | 0.1564 |
10959 | TMED2 | GSM4909308 | Human | Breast | IDC | 6.05e-25 | 5.27e-01 | 0.158 |
10959 | TMED2 | GSM4909309 | Human | Breast | IDC | 7.42e-06 | -2.58e-01 | 0.0483 |
10959 | TMED2 | GSM4909311 | Human | Breast | IDC | 4.24e-46 | -3.10e-02 | 0.1534 |
10959 | TMED2 | GSM4909312 | Human | Breast | IDC | 4.86e-62 | 7.91e-01 | 0.1552 |
10959 | TMED2 | GSM4909313 | Human | Breast | IDC | 4.26e-20 | 4.02e-01 | 0.0391 |
10959 | TMED2 | GSM4909319 | Human | Breast | IDC | 5.03e-62 | -4.82e-01 | 0.1563 |
10959 | TMED2 | GSM4909320 | Human | Breast | IDC | 1.39e-13 | -6.68e-01 | 0.1575 |
10959 | TMED2 | GSM4909321 | Human | Breast | IDC | 1.05e-24 | 1.72e-01 | 0.1559 |
10959 | TMED2 | brca3 | Human | Breast | Precancer | 4.99e-02 | 2.68e-01 | -0.0263 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000184112 | Prostate | Tumor | neural tube formation | 33/3246 | 102/18723 | 1.60e-04 | 1.44e-03 | 33 |
GO:007217512 | Prostate | Tumor | epithelial tube formation | 39/3246 | 132/18723 | 3.66e-04 | 2.86e-03 | 39 |
GO:006071112 | Prostate | Tumor | labyrinthine layer development | 17/3246 | 44/18723 | 6.56e-04 | 4.66e-03 | 17 |
GO:000690113 | Prostate | Tumor | vesicle coating | 9/3246 | 17/18723 | 8.89e-04 | 5.93e-03 | 9 |
GO:001402012 | Prostate | Tumor | primary neural tube formation | 29/3246 | 94/18723 | 9.27e-04 | 6.10e-03 | 29 |
GO:000702912 | Prostate | Tumor | endoplasmic reticulum organization | 27/3246 | 87/18723 | 1.24e-03 | 7.83e-03 | 27 |
GO:000189313 | Prostate | Tumor | maternal placenta development | 14/3246 | 35/18723 | 1.30e-03 | 8.19e-03 | 14 |
GO:000184312 | Prostate | Tumor | neural tube closure | 27/3246 | 88/18723 | 1.50e-03 | 9.25e-03 | 27 |
GO:006060612 | Prostate | Tumor | tube closure | 27/3246 | 89/18723 | 1.80e-03 | 1.06e-02 | 27 |
GO:002191512 | Prostate | Tumor | neural tube development | 41/3246 | 152/18723 | 1.91e-03 | 1.12e-02 | 41 |
GO:000690313 | Prostate | Tumor | vesicle targeting | 16/3246 | 45/18723 | 2.59e-03 | 1.43e-02 | 16 |
GO:003526412 | Prostate | Tumor | multicellular organism growth | 36/3246 | 132/18723 | 2.85e-03 | 1.55e-02 | 36 |
GO:000300711 | Prostate | Tumor | heart morphogenesis | 60/3246 | 246/18723 | 2.99e-03 | 1.61e-02 | 60 |
GO:004819412 | Prostate | Tumor | Golgi vesicle budding | 6/3246 | 10/18723 | 3.00e-03 | 1.61e-02 | 6 |
GO:004820712 | Prostate | Tumor | vesicle targeting, rough ER to cis-Golgi | 7/3246 | 13/18723 | 3.02e-03 | 1.61e-02 | 7 |
GO:004820812 | Prostate | Tumor | COPII vesicle coating | 7/3246 | 13/18723 | 3.02e-03 | 1.61e-02 | 7 |
GO:006013514 | Prostate | Tumor | maternal process involved in female pregnancy | 20/3246 | 62/18723 | 3.07e-03 | 1.63e-02 | 20 |
GO:004819912 | Prostate | Tumor | vesicle targeting, to, from or within Golgi | 9/3246 | 21/18723 | 5.54e-03 | 2.61e-02 | 9 |
GO:000703013 | Prostate | Tumor | Golgi organization | 40/3246 | 157/18723 | 6.33e-03 | 2.90e-02 | 40 |
GO:00606741 | Prostate | Tumor | placenta blood vessel development | 11/3246 | 30/18723 | 9.05e-03 | 3.91e-02 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMED2 | SNV | Missense_Mutation | c.461N>A | p.Arg154Gln | p.R154Q | Q15363 | protein_coding | deleterious(0.03) | benign(0.319) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
TMED2 | SNV | Missense_Mutation | c.542T>A | p.Val181Asp | p.V181D | Q15363 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-BH-A1F5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TMED2 | SNV | Missense_Mutation | c.142G>C | p.Glu48Gln | p.E48Q | Q15363 | protein_coding | tolerated(0.2) | possibly_damaging(0.654) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
TMED2 | SNV | Missense_Mutation | novel | c.253C>G | p.His85Asp | p.H85D | Q15363 | protein_coding | tolerated(0.09) | benign(0.022) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TMED2 | SNV | Missense_Mutation | c.319N>T | p.Met107Leu | p.M107L | Q15363 | protein_coding | tolerated(0.15) | benign(0.046) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
TMED2 | SNV | Missense_Mutation | c.299C>T | p.Thr100Ile | p.T100I | Q15363 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TMED2 | SNV | Missense_Mutation | c.131G>A | p.Gly44Asp | p.G44D | Q15363 | protein_coding | deleterious(0.04) | possibly_damaging(0.876) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
TMED2 | SNV | Missense_Mutation | novel | c.532C>T | p.Leu178Phe | p.L178F | Q15363 | protein_coding | tolerated(0.4) | benign(0.023) | TCGA-4E-A92E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMED2 | SNV | Missense_Mutation | novel | c.130G>T | p.Gly44Cys | p.G44C | Q15363 | protein_coding | deleterious(0.03) | probably_damaging(0.983) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMED2 | SNV | Missense_Mutation | c.272A>G | p.Lys91Arg | p.K91R | Q15363 | protein_coding | tolerated(0.29) | benign(0.022) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |